Crossmark

Distinct pathway activities are associated with prognosis and response to bortezomib-containing treatment in MCL1-M based molecular subtypes of multiple myeloma

Crossref DOI link: https://doi.org/10.1007/s00277-024-06009-y

Published Online: 2024-09-21

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Yuan

Jiang, Sitao

Du, Hang

Tang, Jingling

Xiao, Pengli

Wu, Yin

Li, Jiuyi

Feng, Jing

Wei, Yanfei

Samo, Ayaz Ali

Lu, Xuzhang

Fan, Xiaolong
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82260584, 81773015)

National Key Research and Development Program of China (2019YFE0108100)
License Information

Text and Data Mining valid from 2024-09-21

Version of Record valid from 2024-09-21
More Information

Article History

Received: 28 February 2024

Accepted: 11 September 2024

First Online: 21 September 2024

Declarations

:

: This research was in line with the Declaration of Helsinki and approved by the Ethics Committee at Beijing Chao-Yang Hospital and Guizhou Medical University Hospital. Written informed consent was obtained from all participants.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below